How to predict early mortality in patients with metastatic melanoma
Open Access
- 14 July 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Abstract
Melanoma is the most common malignant tumor, with a large patient population. Metastatic melanoma typically occurs in sites such as lymph nodes, skin, lungs, liver, brain, and bones. This metastatic spread often indicates advanced disease, with significantly decreased treatment efficacy and patient survival rates. Accurately predicting the early death (six months) rates of patients with metastatic melanoma to guide the selection of optimal treatment strategies is an urgent clinical issue in need of resolution. Patient demographic and clinical information for this study was extracted from the SEER database. Univariate and multivariate logistic regression analyses were used to screen for independent risk factors. Operating Characteristic curve (ROC) and calibration curve were used to validate the accuracy of the model. Decision curve analysis (DCA) was used to assess the model’s benefit to patients. Finally, Kaplan-Meier survival curves were plotted to show differences in patient survival across risk groups. A total of 1109 patients were included in the study and randomly allocated to a training cohort (n = 777) and a validation cohort (n = 332). Logistic regression analysis identified six variables as independent factors influencing short-term survival in patients with metastatic melanoma, which were used to construct a nomogram. The Receiver Operating Characteristic (ROC) curve demonstrated good performance of the nomogram in both the training cohort (AUC = 0.755) and the validation cohort (AUC = 0.694). The calibration curve showed good fit. Decision curve analysis (DCA) indicated that patients can derive significant benefit from using this nomogram. We have successfully developed and well validated a nomogram that accurately predicts early death (6 months) in patients with transformational melanoma. This can assist clinicians in choosing better clinical strategies for their patients.Keywords
This publication has 29 references indexed in Scilit:
- External validation in an Australian population of the EORTC-DeCOG nomogram predicting recurrence, distant metastasis and overall mortality in melanoma patients with positive sentinel lymph nodesEuropean Journal of Cancer, 2023
- A simple nomogram for predicting occult lymph node metastasis of non-small cell lung cancer from preoperative computed tomography findings, including the volume-doubling timeSurgery Today, 2023
- European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022European Journal of Cancer, 2022
- Melanoma: An update on systemic therapiesJournal of the American Academy of Dermatology, 2022
- Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)European Journal of Cancer, 2021
- Targeted Therapy and Immunotherapy for Melanoma in JapanCurrent Treatment Options in Oncology, 2019
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaCell, 2016
- Chemotherapy in the management of advanced cutaneous malignant melanomaClinics in Dermatology, 2013
- Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humansSeminars in Immunology, 2012
- Nomograms for Bladder CancerEuropean Urology, 2008